TAIPEI, TAIWAN - Media OutReach
- November 5, 2018 - Insilico Medicine, a Rockville-based company developing an
end-to-end drug discovery pipeline utilizing next-generation artificial
intelligence (AI), was invited to speak at the 6th Healthcare and Life Sciences
Leadership Summit, held on November first and second in Shanghai, China.
Renaissance's 6th Healthcare and Life Sciences Leadership Summit - The
role of AI in driving innovation and transformation of the healthcare sector. (From left: Zhi Xiao, Director of China's State Development & Investment
Corporation (SDIC), moderator of this session; Artur Kadurin, Chief AI Officer
of Insilico Medicine and CEO of Insilico Taiwan; Xing He, Partner of Highlight
Capital; Shigong Kong, Vice President of Beijing Allcure Medical; Lipeng Lai,
co-founder of Big Data R&D at
XtalPl; and Shaodian Zhang, founder and CEO of Synyi AI)
The Summit is hosted by China Renaissance Group, a leading investment
bank with investments in high-growth sectors including technology and
healthcare, and is one of China's most prestigious annual events. Over the course of this year's two-day
program, which included three keynote speeches, 16 panel sessions and 16
roadshow presentations, hundreds of leaders from the global biomedicine and
healthcare sectors shared their latest insights and analysis on current trends
and the state of the industry.
Artur Kadurin, Chief AI
Officer of Insilico Medicine and CEO of Insilico Taiwan, was invited to present
on the opening day of the Summit, at the session titled, "The role of AI in
driving innovation and transformation of the healthcare sector." The session was moderated by Zhi Xiao, Director
of China's State Development & Investment Corporation (SDIC), and featured
panelists Xing He, Partner of Highlight Capital; Shigong Kong, Vice President
of Beijing Allcure Medical; Lipeng Lai, co-founder of Big Data R&D at
XtalPl; and Shaodian Zhang, founder and CEO of Synyi AI. The group of
distinguished panelists discussed the key role that AI is playing as the new
driver transforming the future of healthcare from the perspective of industry,
Moderator Zhi Xiao noted that
China's capital markets were very hot in the first half of the year, but
experienced a dramatic slowdown in the second half. Nevertheless, the "AI" topic, hot since 2017,
remains so and is "the" keyword for VC and PE investment, especially in the
fields of biomedicine and healthcare. Recent data revealed that at least 31 AI
companies have successfully completed 34 rounds of fundraising, totaling
over US $400 million raised.
AI has been through three
major ups and downs since the 1960s.
Most recently, technology breakthroughs in pattern recognition have shown
the greatest promise in future applications in therapeutics and diagnosis. Artur Kadurin, Chief AI Officer of Insilico
Medicine and CEO of Insilico Taiwan said: "AI has had great success in computer
vision and now outperforms humans. For example, we can currently
apply AI to image pattern recognition for cancer screening." Many new AI applications in biomedicine and
healthcare have also been developed rapidly, such as drug discovery, robotics
care, electronic health records, precision diagnosis and therapy, and telemedicine.
In support of Mr. Kadurin's viewpoint, Beijing Allcure Medical recently
received an investment of over RMB 700 million from a state-owned fund. This is the first time that China's state
funds have been invested in a corporate platform focused on leveraging AI in
radiation therapy for cancer. Additionally,
Highlight Capital also invested in a number of startups using AI in molecular
diagnosis and gene sequencing. In short,
investment trends suggest that patient-doctor interactions and hospital operations
are being completely revolutionized as AI successfully masters precision diagnosis.
As human life expectancy continues to increase, aging well has become one of the newest and hottest
topics in healthcare today. Insilico Medicine has invested a great deal of
effort in anti-aging studies using AI. Mr.
Kadurin emphasized, "Since the rise of deep learning, AI systems
have shown great potential and have outperformed humans in many health-related
fields. I think it's time to use AI for
creating super-man health."
About Insilico Medicine, Inc.
Insilico Medicine is an artificial
intelligence company with R&D offices and resources in the US, Belgium,
Russia, the UK, Taiwan and Korea, sourced through hackathons and competitions.
The company and its scientists are dedicated to extending human productive
longevity and transforming every step of the drug discovery and drug
development process through excellence in biomarker discovery, drug
development, digital medicine and aging research.
Insilico pioneered the applications of the
generative adversarial networks (GANs) and reinforcement learning for
generation of novel molecular structures for diseases with a known ligand and
with no known targets. In addition to working collaborations with large
pharmaceutical companies, the company is pursuing internal drug discovery
programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease,
Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a
partnership with LifeExtension.com the company launched a range of
nutraceutical products, compounded using advanced bioinformatics and deep
learning techniques. It also provides a range of consumer-facing applications,
In 2017, NVIDIA selected Insilico Medicine as
one of the Top 5 AI companies for potential in social impact. In 2018, the
company was named one of the global top 100 AI companies by CB Insights. In
2018 it received the Frost & Sullivan 2018 North American Artificial
Intelligence for Aging Research and Drug Development Award accompanied by
Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8
Roger Lai, Consultant